PREDICTION METHOD OF THERAPY EFFECTIVENESS IN PATIENTS WITH PAROXYSMAL SCHIZOPHRENIA Russian patent published in 2017 - IPC A61B5/476 G01N33/53 

FIELD: medicine.

SUBSTANCE: electroencephalogram (EEG) is registered before therapy initiation in paroxysmal schizophrenia patients with manic-delusional disorders. Immunological study of autoantibodies content to myelin basic protein (AAB MPB) is additionally carried out. Quantitative values of absolute power spectrum are determined during EGG study in theta2, alpha1, alpha2, alpha3, beta2 EEG frequency sub-bands in EEG leads: in the left frontal, mid-temporal, left parietal and occipital leads. The resulting values are calculated according to the formulas of multiple linear regression equations X₁, X₂ and X₃ in c.u. When the X₁ value is less than 28 c.u., the X₂ value is less than 28 c.u. and the X₃ value is less than 120 c.u., satisfactory effectiveness of standard syndrome-related therapy is predicted. In paroxysmal schizophrenia patients with hallucinatory-delusional disorders, the quantitative values of absolute power spectrum are determined during EGG study in delta, theta1, alpha2, alpha3, beta1 EEG frequency sub-bands in EEG leads: in the frontal, mid-temporal, parietal and occipital (O1, O2) leads. Immunological study of autoantibodies content to nerve growth factor - S100B protein (AAB NGF) and to myelin basic protein (AAB MPB) is carried out. The resulting values are calculated according to the formulas of multiple linear regression equations X₄, X₅ and X₆ in c.u. When the X₄ value is less than 28 c.u., the X₅ value is less than 28 c.u. and the X₆ value is less than 120 c.u., satisfactory effectiveness of standard syndrome-related therapy is predicted.

EFFECT: invention enables to improve the accuracy of prediction before therapy order to a patient, which is achieved by taking into account the complex of individual neurophysiological and biochemical parameters.

2 cl, 2 ex